Works matching IS 1044307X AND DT 2022 AND VI 34 AND IP 2
Results: 6
Late-onset recurrence in breast cancer: Implications for women's health clinicians in survivorship care: Data show that late-onset recurrence is more likely among patients with an initial tumor size >2 cm, lymph node-positive disease, and hormone receptor-positive tumors
- Published in:
- OBG Management, 2022, v. 34, n. 2, p. 46, doi. 10.12788/obgm.0172
- By:
- Publication type:
- Article
Embryo mix-up debacles: Is there liability? A discussion of IVF-related injuries and the evolving legal considerations.
- Published in:
- OBG Management, 2022, v. 34, n. 2, p. 38, doi. 10.12788/obgm.0170
- By:
- Publication type:
- Article
Vitamin supplementation in healthy patients: What does the evidence support? This review, with handy tables, summarizes which vitamins offer proven benefits--and which don't.
- Published in:
- OBG Management, 2022, v. 34, n. 2, p. 28, doi. 10.12788/jfp.0288
- By:
- Publication type:
- Article
HT for women who have had BSO before the age of natural menopause: Discerning the nuances.
- Published in:
- OBG Management, 2022, v. 34, n. 2, p. 20, doi. 10.12788/obgm.0174
- By:
- Publication type:
- Article
Does the promised utility of endometrial receptivity testing pan out? Plus, a review of a common disease associated with infertility.
- Published in:
- OBG Management, 2022, v. 34, n. 2, p. 15, doi. 10.12788/obgm.0173
- By:
- Publication type:
- Article
Drospirenone vs norethindrone progestinonly pills. Is there a clear winner? Among progestin-only contraceptive pills, compared to norethindrone, drospirenone has superior performance on key dimensions.
- Published in:
- OBG Management, 2022, v. 34, n. 2, p. 10, doi. 10.12788/obgm.0171
- By:
- Publication type:
- Article